Abstract: A pressure-activated membrane switch and methods of use are provided. The pressure-activated membrane switch includes an electrically-conductive membrane, and a compliant conductive material having an electrically-conductive inner surface, wherein contact between the electrically-conductive membrane and the electrically-conductive inner surface of the compliant material is configured to cause an electrical circuit, of which the switch is a part, to close. The pressure-activated membrane switch further includes a plurality of spacers dispersed between the electrically-conductive membrane and the compliant conductive material. The plurality of spacers form one or more gaps between the electrically-conductive membrane and the compliant conductive material, and, with an application of pressure against the compliant conductive material, the compliant conductive material is configured to deform between the one or more gaps to contact the electrically-conductive membrane.

Abstract: Disclosed herein are iron oxide nanoparticles having an iron (II) content in a metastable state that is intermediate the iron (II) content of wüstite and magnetite. The disclosed iron oxide nanoparticles exhibit unexpectedly beneficial magnetic properties (e.g., saturation magnetization) resulting from both the size of the nanoparticles and the iron (II) content. Accordingly, the iron oxide nanoparticles are attractive for magnetic imaging applications, such as magnetic particle imaging. Methods of forming the iron oxide nanoparticles are also provided, such methods including a controlled oxidation step wherein a small amount (e.g., 1%) of gaseous oxygen is exposed to wüstite nanoparticles for a defined period of time sufficient to partially oxidize the wüstite but prevent conversion entirely to magnetite. Finally, methods of using the iron oxide nanoparticles are also provided. Representative methods include magnetic particle imaging, magnetic resonance imaging, and hyperthermia.

Abstract: A calcium/cation-sensing receptor (CaSR) antagonist to treat an inflammatory lung disorder is described. Methods of treatment including the antagonist, combination therapeutics including the antagonist and at least one other agent, and nebulizers or inhalers including the antagonist are also described.

Abstract: The invention concerns a calcium/cation-sensing receptor (CaSR) antagonist to treat an inflammatory lung disorder; a method of treatment involving said antagonist; a combination therapeutic comprising said antagonist and at least one other agent; and a nebuliser or inhaler containing same.

Abstract: A calcium/cation-sensing receptor (CaSR) antagonist to treat an inflammatory lung disorder is described. Methods of treatment including the antagonist, combination therapeutics including the antagonist and at least one other agent, and nebulisers or inhalers including the antagonist are also described.

Abstract: A first storage server head and a second storage server head are operated and are configured redundantly to provide a host with access to a plurality of mass storage devices. A diagnostic process is executed in the first storage server head to assess operational status of the second storage server head while the second storage server head is in a mode for providing the host with access to the plurality of mass storage devices.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and an optionally substituted heteroaryl group at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.

Abstract: Conjugates, compositions and methods for treatment, prevention, or amelioration of one or more symptoms of cell surface protease-related diseases, including MTSP-related, urokinase-type plasminogen activator (uPA) or endotheliase-related diseases, are provided. The conjugates for use in the compositions and methods are peptidic conjugates that contain therapeutic, including cytotoxic, agents.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention provides compounds which have a pyrazinone or pyridinone ring at P3 and an optionally substituted heteroaryl group at P1. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.

Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.